PubRank

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

Clinical Trial ID NCT02000947

PubWeight™ 17.27‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02000947

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016 2.06
2 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
3 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
4 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
5 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
6 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
7 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
8 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
9 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
10 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
11 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
12 Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014 0.85
13 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
14 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
15 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
16 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
17 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
18 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
Next 100